Advertisement
Home »

Benefit of Pembrolizumab in TNBC Remains At 5 Years

Oct 25, 2023

REFERENCES & ADDITIONAL READING

Schmid P, Cortes J, Pusztai L, et al. N Engl J Med. 2020;382:810-821. DOI: 10.1056/NEJMoa1910549

 

Cortes J, Rugo HS, Cescon DW, et al. N Engl J Med. 2022;387:217-226. DOI: 10.1056/NEJMoa2202809

 

Schmid P, Cortés J, Dent R, et al. Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study. Abstract LBA18, ESMO 2023, 20-24 October, Madrid, Spain.

 

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement